Under the collaboration, Daiichi will utilize Cyntellect’s high-throughput cell imaging and laser-based cell manipulation technology, LEAP, for novel drug discovery. Cyntellect will design, configure and run LEAP cell-based assays against a compound collection provided by Daiichi.
“We are pleased to establish a formal research relationship with Daiichi, one of Japan’s leading pharmaceutical companies,” stated Dr Fred Koller, president and CTO of Cyntellect. “Daiichi’s commitment to Cyntellect and LEAP represents another important validation of our technology and highlights the unique value proposition presented by combining imaging and cell manipulation in the process of discovering new therapeutics.”
The collaboration will combine Daiichi’s long-established drug development know-how with Cyntellect’s expertise in high-speed cell imaging and laser-based manipulation, to develop products to enhance productivity in areas including laboratory research, protein production, functional genomics and cell purification.